

Instant detection of vision-threatening eye diseases using artificial intelligence


For better perception

iCare ILLUME

Fast and effortless screening for eye diseases in all care settings

Why use artificial intelligence in screening?

- Artificial intelligence (AI) provides efficient processing for higher throughput
- AI detects early signs of retinal pathologies instantly and classifies the results according to severity
- AI allows ophthalmologists to focus on patients who are most in need of specialized care
- Our Al partner Thirona B.V. provides results that match the level of a professional human grader
- Al generates heatmaps as a supportive system for human experts to review and interpret visual indications



Disclaimers

When more than mild Diabetic Retinopathy (DR ≥ 2) or more than Early Age-related Macular Degeneration (AMD ≥ 2) or suspicion of Glaucoma (GLC ≥ 0.5) is detected, it is recommended to see an eye-care specialist for follow-up diagnosis. The RetCAD[™] software is approved for clinical use and is CE (0344) certified as a Class IIa medical device. The analysis using RetCAD™ does not replace an eye-health check-up.

This report was generated using RetCAD[™] v2.0.2, CE (0344), Thirona Retina

The iCare Screening Solution allows fast and effortless screening for diabetic retinopathy, AMD and glaucoma

- High-quality images taken with iCare DRSplus* meet the requirements of AI on the first take
- Swift, fully automated operations result in significant timesaving
- Dilation is not needed, and imaging is successful even in patients with media opacities
- More focused and controlled referral flow



Enabling digital screening pathways

- Practice owners can offer screening as a new service
- Results can be stored in most widely used electronic health record systems, improving communication
- Referrals can be shared outside your organization, improving care compliance
- · Data security and privacy meet the highest standards

Swift, fully automated operations



- 1. The iCare DRSplus fundus imaging system is intuitive and requires minimal staff training.
- 2. High-quality images are automatically stored and forwarded for processing by AI.



3. The report is instantly available and can be discussed with the patient during the same visit.

* iCare DRSplus fundus imaging system, using iCare TrueColor Confocal Technology

iCare. For better perception.

iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). Our devices cover automated fundus imaging systems, perimeters, and handheld rebound tonometers. iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

We believe that ophthalmic care must be accessible, effortless, and reliable, and our aim is to establish the next level of eye care.

iCare World Australia

Level 9, 276 Flinders Street Melbourne Victoria 3000, Australia Ph. +61 3 85927079 infoAU@icare-world.com

Centervue S.p.A.

Via San Marco 9H 35129 Padova, Italy Ph. +39 049 501 8399 info@icare-world.com

Icare Finland Oy

Äyritie 22 01510 Vantaa, Finland Ph. +358 9 8775 1150 info@icare-world.com

Icare USA, Inc.

4700 Falls of Neuse Rd. Ste 245 Raleigh, NC. 27609 Ph. +1 888.422.7313 Fax +1 877.477.5485 infoUSA@icare-world.com

www.icare-world.com



iCare is a trademark of Icare Finland Oy. Icare Finland Oy, Icare USA, Inc., iCare World Australia Pty Ltd and Centervue S.p.A., are parts of Revenio Group and represent the brand iCare. ICare ILLUME is a trademark or a registered trademark of Icare Finland Oy in the EU and the USA and/or other countries. Centervue S.P.A. is the legal manufacturer of DRSplus Not all products, accessories, services or offers are approved in every market. Approved labelling and instructions may vary from one country to another. This material is intended for healthcare professionals only. © 2023 Icare Finland Oy. All rights reserved.